Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma

Cited by (336)

Items 101–200 of 336

1. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies
   Stephens, Deborah M., Byrd, John C. · 2021 · Blood
2. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
   Michele Stanchina, Skye Montoya, Alexey Valeryevich Danilov, Jorge Julio Castillo, Alvaro Jose Alencar, Julio C. Chavez, Chan Yoon Cheah, CARLOS SÉRGIO CHIATTONE, Yucai Wang, Meghan C. Thompson et al. · 2024 · Nature Reviews Clinical Oncology
3. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma
   Atish Ranjan Mohanty, Natalie Sandoval, An T. Phan, Thang Van Nguyen, Robert W. Chen, Lihua Elizabeth Budde, Matthew Genyeh Mei, Leslie L. Popplewell, Lan V. Pham, Larry W. Kwak et al. · 2018 · Blood
4. The Need for a Consensus Next‐generation Sequencing Panel for Mature Lymphoid Malignancies
   Pierre Sujobert, Yannick Le Bris, Laurence de Leval, Audrey Gros, Jean Philippe Merlio, Cédric Pastoret, Sarah Huet, Clémentine Sarkozy, Frédéric Davi, Mary B. Callanan et al. · 2019 · HemaSphere
5. Ibrutinib
   Andriani Charalambous, Mark‐Alexander Schwarzbich, Mathias Witzens‐Harig · 2018 · Recent results in cancer research/Recent Results in Cancer Research
6. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
   Changying Jiang, Yang Liu, Junwei Lian, Shengjian Huang, Alexa A Jordan, Qingsong Cai, Ruitao Lin, Fangfang Yan, Joseph Mitchell McIntosh, Yijing Li et al. · 2023 · Journal of Clinical Investigation
7. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
   Yoko Tabe, Kensuke Kojima, Shinichi Yamamoto, Kazumasa Sekihara, Hiromichi Matsushita, Richard Eric Davis, Zhiqiang Wang, Wencai Ma, Jo Ishizawa, Saiko Kazuno et al. · 2015 · PLoS ONE
8. Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities
   Alexander N.R. Weber, Yamel Cardona Gloria, Özcan Çınar, Hans Christian Reinhardt, Antonio Pezzutto, Olaf‐Oliver Wolz · 2018 · Cancer Immunology Immunotherapy
9. ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma
   Makhdum Ahmed, Lei Li, Chelsea Camille Pinnix, Bouthaina S. Dabaja, Krystle J. Nomie, Laura T Lam, Michael L. Wang · 2016 · Critical Reviews in Oncology/Hematology
10. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
    Eugenio Gaudio, Chiara Tarantelli, Ivo Kwee, Chiara Barassi, Elena Bernasconi, Andrea Rinaldi, Maurilio Ponzoni, Luciano Cascione, A. Targa, Anastasios Stathis et al. · 2016 · Annals of Oncology
11. The noncanonical NFκB pathway: Regulatory mechanisms in health and disease
    Benancio N. Rodriguez, Helen J. Huang, Jennifer J. Chia, Alexander Hoffmann · 2024 · WIREs Mechanisms of Disease
12. Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives
    T. Seiler, Martin H. Dreyling · 2017 · Expert Opinion on Investigational Drugs
13. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
    Pavel Klener · 2019 · International Journal of Molecular Sciences
14. Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma
    Philip Bucher, Tabea Erdmann, Paula Grondona, Wendan Xu, Anja Schmitt, Christoph Schürch, Myroslav Zapukhlyak, Caroline Schönfeld, Edgar Serfling, Daniela Kramer et al. · 2019 · Blood
15. Combining precision oncology and immunotherapy by targeting the MALT1 protease
    Thorsten R. Mempel, Daniel Krappmann · 2022 · Journal for ImmunoTherapy of Cancer
16. The RCAN1 inhibits NF-κB and suppresses lymphoma growth in mice
    C Liu, Libo Zheng, Hongliang Wang, Xuehong Ran, Huan Liu, Xiulian Sun · 2015 · Cell Death and Disease
17. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
    Stefan Koehrer, Jan A. Burger · 2016 · PubMed
18. Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo
    Hong Qin, Guo‐Wei Wei, Ippei Sakamaki, Zhenyuan Dong, Wesley A. Cheng, Diane Lynne Smith, Feng Wen, Han Sun, Kunhwa Kim, Soung-chul Cha et al. · 2017 · Clinical Cancer Research
19. Oncogenic activity of BIRC 2 and BIRC 3 mutants independent of nuclear factor‐κB‐activating potential
    Azusa Yamato, Manabu Soda, Toshihide Ueno, Shinya Kojima, Kyuto Sonehara, Masahito Kawazu, Eirin Sai, Yoshihiro Yamashita, Takahide Nagase, Hiroyuki Mano · 2015 · Cancer Science
20. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
    Daniel Nagel, Miriam Bognar, Andrea C. Eitelhuber, Kerstin Kutzner, Michelle Vincendeau, Daniel Krappmann · 2015 · Oncotarget
21. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma
    Sı́lvia Beà, Virginia Amador · 2017 · Current Oncology Reports
22. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
    Young‐Woo Jeon, Seugyun Yoon, Gi June Min, Sung‐Soo Park, Silvia Park, Jae‐Ho Yoon, Sung‐Eun Lee, Byung‐Sik Cho, Ki‐Seong Eom, Yoo‐Jin Kim et al. · 2019 · Cancer Medicine
23. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma
    Warren C. Fiskus, Christopher Peter Mill, Dimuthu Nuwan Perera, Christine E. Birdwell, Qing Deng, Haopeng Yang, Bernardo H Lara, Nitin Jain, Jan A. Burger, Alessandra Ferrajoli et al. · 2021 · Leukemia
24. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
    Deborah Marie Stephens, Stephen E. F. Spurgeon · 2015 · Therapeutic Advances in Hematology
25. Molecular pathogenesis of splenic and nodal marginal zone lymphoma
    Valeria Spina, Davide Rossi · 2016 · Best Practice & Research Clinical Haematology
26. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
    Marthe Minderman, Hildo C. Lantermans, Leonie J. Grüneberg, Saskia A.G.M. Cillessen, Richard J. Bende, Carel J.M. van Noesel, Marie José Kersten, Steven T. Pals, Marcel Spaargaren · 2023 · Blood Cancer Journal
27. The role of B cell antigen receptors in mantle cell lymphoma
    Michael W. Fichtner, Martin H. Dreyling, Mascha Binder, Martin Trepel · 2017 · Journal of Hematology & Oncology
28. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
    Carrie J. Li, Changying Jiang, Yang Liu, Taylor Bell, Wencai Ma, Yin Ye, Shengjian Huang, Hui Guo, Hui Zhang, Lai Wang et al. · 2018 · Molecular Cancer Therapeutics
29. Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas
    Lapo Alinari, Carl D. Quinion, KA Blum · 2015 · Clinical Pharmacology & Therapeutics
30. Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma
    Katarzyna Tomska, Roman Kurilov, Kwang-Seok Lee, Jennifer Hüllein, Marina Lukas, Leopold Sellner, Tatjana Walther, Lena Wagner, Małgorzata Oleś, Benedikt Brors et al. · 2018 · Scientific Reports
31. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
    Alessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, Brendan Paul Hodkinson, Gabriela Forestieri, Ferdinando Bonfiglio, Adalgisa Condoluci, Wei Wu, Maria Cristina Pirosa, Martin Faderl et al. · 2021 · Blood Advances
32. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas
    Sai Krishna Athaluri Divakar, M. V. Ramana Reddy, Stephen C. Cosenza, Stacey J. Baker, Deepal Perumal, Anthony C. Antonelli, Joshua Brody, Benjamin Akula, Samir Sunil Parekh, E. Premkumar Reddy · 2015 · Leukemia
33. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma
    Hanna Karvonen, David Chiron, Wilhelmiina Niininen, Sara Ek, Mats Jerkeman, Elaheh Moradi, Matti Nykter, Caroline Akemi Heckman, Olli Kallioniemi, Astrid Murumägi et al. · 2017 · Blood Advances
34. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
    Elana Thieme, Tingting Liu, Nur Bruss, Carly Roleder, Vi Lam, Xiaoguang Wang, Tamilla Nechiporuk, Geoffrey Shouse, Olga V. Danilova, Daniel Bottomly et al. · 2022 · Cell Death and Disease
35. The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications
    Diana Giannuzzi, Laura Marconato, Antonella Fanelli, Luca Licenziato, Raffaella De Maria, Andrea Rinaldi, Luca Rotta, Nicole Rouquet, Giovanni Birolo, Piero Fariselli et al. · 2022 · Lab Animal
36. Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
    Neeraj Kumar Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla · 2023 · Journal of Hematology & Oncology
37. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
    Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, Luciano Cascione, Valentina Restelli, Alberto J. Arribas, Filippo Spriano, Andrea Rinaldi, Afua A. Mensah, Ivo Kwee et al. · 2018 · ESMO Open
38. Mechanisms of NF-κB deregulation in lymphoid malignancies
    Daniel Krappmann, Michelle Vincendeau · 2016 · Seminars in Cancer Biology
39. CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma
    Hilka Rauert‐Wunderlich, Martina Rudelius, Ingolf Berberich, Andreas Rosenwald · 2018 · Cell Death and Disease
40. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma
    Hui Guo, Dongfeng Zeng, Hui Zhang, Taylor Bell, Jun Yao, Yang Liu, Shengjian Huang, Carrie J. Li, Elizabeth Lorence, Shouhao Zhou et al. · 2018 · Oncogene
41. p110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
    Jiyu Guan, Dan Huang, Konstantin Yakimchuk, Sam Okret · 2018 · Molecular Cancer Therapeutics
42. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials
    Mouhamad Khouja, Linmiao Jiang, Karol Pál, Peter James Stewart, Binaya Regmi, Martin Schwarz, Wolfram Klapper, Stefan Alig, Nikos Darzentas, Hanneke C. Kluin‐Nelemans et al. · 2024 · Leukemia
43. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A /B loss, and TP53 mutations: A multi‐institutional study
    Lukas D. Streich, Madina Jh. SUKHANOVA, Xinyan Lu, Yi‐Hua Chen, Girish Venkataraman, Stephanie P. Mathews, Shanxiang Zhang, Katalin Kelemen, Jeremy P. Segal, Juehua Gao et al. · 2020 · Genes Chromosomes and Cancer
44. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies
    Marina Lukas, Britta Velten, Leopold Sellner, Katarzyna Tomska, Jennifer Hüellein, Tatjana Walther, Lena Wagner, Carolin Muley, Bian Wu, Małgorzata Oleś et al. · 2020 · Leukemia
45. Management of Drug Resistance in Mantle Cell Lymphoma
    Gaël Roué, Brigitte Sola · 2020 · Cancers
46. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
    Salomé Decombis, Céline Bellanger, Yannick Le Bris, Candice Madiot, Jane Jardine, Juliana Carvalho Santos, Delphine Boulet, Christelle Dousset, Audrey Ménard, Charlotte Kervoëlen et al. · 2023 · Blood
47. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
    Riccardo Bomben, Simone Ferrero, Tiziana D’Agaro, Michele Dal Bo, Alessandro Re, Andrea Evangelista, Angelo Michele Carella, Alberto Zamò, Umberto Vitolo, Paola Omedè et al. · 2018 · Haematologica
48. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
    Xiaohong Zhao, Michelle Y. Wang, Huijuan Jiang, Tint Lwin, Paul M.C. Park, Jing Gao, Mark B. Meads, Yuan Ren, Tao Li, Jiao Sun et al. · 2021 · Cell Reports
49. MAP3K Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types
    Khoa Nguyen, Minh N. Tran, Andrew Rivera, Thomas Cheng, Gabrielle O. Windsor, A. Bert Chabot, Jane E. Cavanaugh, Bridgette M. Collins‐Burow, Sean Bong Lee, David Harold Drewry et al. · 2022 · Frontiers in Bioscience-Landmark
50. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
    Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Martine B.W. Prinsen, Yvonne Grobben, Tessa J.J. de Bitter, Antoon M. van Doornmalen, Janneke J. T. M. Melis, Joost C.M. Uitdehaag, Yugo Narumi et al. · 2022 · Frontiers in Oncology
51. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
    Maciej Tatarczuch, Mark C. Waltham, Jake Shortt, Galina Polekhina, Eliza Anne Hawkes, Shir‐Jing Ho, Judith Trotman, Daniella Brasacchio, Melannie Co, Jessica L. Li et al. · 2023 · Blood Advances
52. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment
    Ekaterina Kim, Elisa ten Hacken, Mariela Sivina, Astrid S. Clarke, Philip A. Thompson, Nitin Jain, Alessandra Ferrajoli, Zeev E. Estrov, Michael J. Keating, William G. Wierda et al. · 2019 · Leukemia
53. Treatment of relapsed/refractory MCL
    Elisabeth Silkenstedt, Martin H. Dreyling · 2024 · Blood
54. High-risk MCL: recognition and treatment
    Preetesh Jain, Michael L. Wang · 2024 · Blood
55. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
    Jeffrey Wang, Jacqueline Wang, Elyse Lopez, Hui Guo, Hui Zhang, Yang Liu, Zhihong Chen, Shengjian Huang, Shouhao Zhou, Angela Leeming et al. · 2019 · Blood Cancer Journal
56. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression
    Miguel Quijada‐Álamo, María Hernández‐Sánchez, Ana E. Rodríguez‐Vicente, Claudia Pérez Carretero, Alberto Rodríguez‐Sánchez, Marta Martín‐Izquierdo, Verónica Alonso-Pérez, Ignacio García‐Tuñón, José María Bastida, María Jesús Vidal-Manceñido et al. · 2021 · Blood Cancer Journal
57. Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
    Khalil Saleh, Morgane Cheminant, David Chiron, Barbara Burroni, Vincent Ribrag, Clémentine Sarkozy · 2022 · Cancers
58. Circulating tumour DNA in B‐cell lymphomas: current state and future prospects
    Rahul Lakhotia, Mark J. Roschewski · 2021 · British Journal of Haematology
59. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment
    Antonin Papin, Steven Le Gouill, David Chiron · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
60. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma
    Cristina López, Elisabeth Silkenstedt, Martin H. Dreyling, Sı́lvia Beà · 2024 · Blood Advances
61. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein
    Jing Cheng, Linda R. Klei, Nathaniel E. Hubel, Ming Zhang, Rebekka Schairer, Lisa M. Maurer, Hanna B. Klei, Heejae Kang, Vincent J. Concel, Phillip C. Delekta et al. · 2020 · Journal of Clinical Investigation
62. NF-κB deregulation in splenic marginal zone lymphoma
    Valeria Spina, Davide Rossi · 2016 · Seminars in Cancer Biology
63. An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase
    Islam Al-Khawaldeh, Mohammed J. Al Yasiri, Gregory G. Aldred, Christine Basmadjian, Cinzia Bordoni, Suzannah J. Harnor, Amy B. Heptinstall, Stephen J. Hobson, Claire Jennings, Shaimaa Khalifa et al. · 2021 · Journal of Medicinal Chemistry
64. BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies
    Xin Liu, Yufan Lin, Qiqi Zhuang, Haoren Deng, Aichun Liu, Jie Sun · 2025 · Blood Reviews
65. The Therapeutic Potential of Targeting NIK in B Cell Malignancies
    Marco Vincent Haselager, Eric Eldering · 2022 · Frontiers in Immunology
66. Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase
    Stephan Hailfinger, Georg Lenz, Margot Thome · 2014 · Current Opinion in Chemical Biology
67. Concomitant high expression of Toll‐like receptor (TLR) and B‐cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma
    Ariz Akhter, Lesley E. Street, Sunita Ghosh, Bruce F. Burns, Ghaleb Elyamany, Meer‐Taher Shabani‐Rad, Douglas Allan Stewart, Adnan Mansoor · 2015 · Hematological Oncology
68. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status
    Anna Vidal‐Crespo, Vanina Rodríguez, Alba Matas‐Céspedes, Eriong Lee‐Vergés, Alfredo Rivas‐Delgado, Eva Giné, Alba Navarro, Sı́lvia Beà, Elı́as Campo, Armando López‐Guillermo et al. · 2017 · Haematologica
69. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials
    Rishu Agarwal, Mark A. Dawson, Martin H. Dreyling, Constantine Si Lun Tam · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
70. Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma
    Aya Maeda, Yuki Nishida, Marla L. Weetall, Liangxian Cao, Arthur A. Branstrom, Jo Ishizawa, Takenobu Nii, Wendy D. Schober, Yoshiaki Abe, Kosei Matsue et al. · 2018 · Oncotarget
71. Targeting Wnt signaling pseudokinases in hematological cancers
    Hanna Karvonen, Robert Perttilä, Wilhelmiina Niininen, Harlan R. Barker, Daniela Ungureanu · 2018 · European Journal Of Haematology
72. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo
    Zhuojun Liu, Jia Liu, Tianming Zhang, Mingxia Shi, Xiaofang Chen, Yun Chen, Jian Yu · 2019 · Pharmacological Research
73. The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition
    Salomé Decombis, Antonin Papin, Céline Bellanger, Clara Sortais, Christelle Dousset, Yannick Le Bris, Thiphanie Riveron, Stéphanie Blandin, Philippe Hulin, Benoît Tessoulin et al. · 2022 · Haematologica
74. Chronic lymphocytic leukaemia genomics and the precision medicine era
    Hussein Ghamlouch, Florence Nguyen‐Khac, Olivier Bernard · 2017 · British Journal of Haematology
75. Precision diagnostics in lymphomas – Recent developments and future directions
    Larry Mansouri, Birna Þorvaldsdóttir, Stamatia Laidou, Κώστας Σταματόπουλος, Richard Rosenquist · 2021 · Seminars in Cancer Biology
76. TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma
    Michael Yu Li, Lauren C. Chong, Gerben Duns, Andrew G. Lytle, Bruce W. Woolcock, Aixiang Jiang, Adèle Telenius, Susana Ben‐Neriah, Waqas Nawaz, Graham W. Slack et al. · 2024 · Proceedings of the National Academy of Sciences
77. On Chip Analysis of CNS Lymphoma in Cerebrospinal Fluid
    Anna Turetsky, Kyungheon Lee, Jun Song, Randy J. Giedt, Eunha Kim, Alexandra E. Kovach, Ephraim P. Hochberg, Cesar Martin Castro, Hakho Lee, Ralph Weissleder · 2015 · Theranostics
78. Do mantle cell lymphomas have an ‘Achilles heel’?
    Nakhle S. Saba, Adrian U. Wiestner · 2014 · Current Opinion in Hematology
79. The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
    Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann, Filippo Spriano, Giulio Sartori, Luca Aresu, Luciano Cascione, Denise Rageot, Ivo Kwee, Florent Beaufils et al. · 2019 · Cancers
80. Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2
    Wenjun Wu, Weige Wang, Carrie A. Franzen, Hui Guo, Jimmy Lee, Yan Li, Madina Jh. SUKHANOVA, Dong Sheng, Girish Venkataraman, Mei Ming et al. · 2021 · Blood Advances
81. The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells
    Martina Rudelius, Hilka Rauert‐Wunderlich, Elena Hartmann, Eva Hoster, Martin H. Dreyling, Wolfram Klapper, German Ott, Andreas Rosenwald · 2015 · Haematologica
82. The Prognosis of Cancer Depends on the Interplay of Autophagy, Apoptosis, and Anoikis within the Tumor Microenvironment
    Shweta Gulia, Prakash Chandra, Asmita Das · 2023 · Cell Biochemistry and Biophysics
83. Safety and diagnostic accuracy of tumor biopsies in children with cancer
    Rodrigo B. Interiano, Amos Hong Pheng Loh, Nathan M. Hinkle, Fazal Nouman Wahid, Alpin D. Malkan, Armita Bahrami, Jesse J. Jenkins, Shenghua Mao, Jianrong Wu, Kimberly E. Proctor et al. · 2014 · Cancer
84. Genetic Variants Influencing Joint Damage in Mexican Americans and European Americans With Rheumatoid Arthritis
    Rector Arya, Inmaculada del Rincón, Vidya S. Farook, José Félix Restrepo, Diedre A Winnier, Marcel J. Fourcaudot, Daniel F Battafarano, Marcio Almeida, Satish Kumar, Joanne E. Curran et al. · 2015 · Genetic Epidemiology
85. TRAF2 Deficiency in B Cells Impairs CD40-Induced Isotype Switching That Can Be Rescued by Restoring NF-κB1 Activation
    Rachel A. Woolaver, Xiaoguang Wang, Yonatan Dollin, Ping Xie, Jing Hong Wang, Zhangguo Chen · 2018 · The Journal of Immunology
86. Drawing Inferences for High-Dimensional Linear Models: A Selection-Assisted Partial Regression and Smoothing Approach
    Zhe Fei, Ji Zhu, Moulinath Banerjee, Yi Li · 2018 · Biometrics
87. Unexpected functions of nuclear factor-κB during germinal center B-cell development
    Ulf Klein, Nicole Heise · 2015 · Current Opinion in Hematology
88. NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
    Alice Bonato, Supriya Chakraborty, Riccardo Bomben, Giulia Canarutto, Giulia Felician, Claudio Martines, Antonella Zucchetto, Federico Pozzo, Marija Vujovikј, Jerry Polesel et al. · 2024 · Leukemia
89. Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma
    Dolors Colomer, Elı́as Campo · 2014 · Cancer Cell
90. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies
    Tsering Gyalpo Lama, Daniel Kyung, Susan Mary O'Brien · 2020 · Expert Review of Hematology
91. Canonical and Non-Canonical Roles of GRK2 in Lymphocytes
    Jing Cheng, Peter C. Lucas, Linda M. McAllister‐Lucas · 2021 · Cells
92. Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies
    Andrés Bravo-González, Maryam Alasfour, Deborah Soong, Jose Noy, Georgios N. Pongas · 2024 · Cancers
93. Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy
    Elsa Maître, Édouard Cornet, Agathe Pruvot Debliquis, Bernard Drénou, François Gravey, Didier Chollet, Stéphane Chèze, Mylène Docquier, Xavier Troussard, Thomas Matthes · 2022 · Journal of Cancer Research and Clinical Oncology
94. Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies
    Anagha J. Deshpande, Javier L Munoz · 2022 · Frontiers in Oncology
95. Chronic lymphocytic leukemia: Time to go past genomics?
    Damien Roos‐Weil, Florence Nguyen‐Khac, Olivier Bernard · 2016 · American Journal of Hematology
96. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species‐ and GSK3β‐dependent mechanism
    Aladin Samara, Saar Shapira, Ido Lubin, Ofer Shpilberg, Smadar Avigad, Galit Granot, Pia Raanani · 2021 · British Journal of Haematology
97. G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Mantle Cell Lymphoma Growth in Preclinical Models
    Lixia Zhou, Tenghua Yu, Fei Yang, Jingjing Han, Bin Zuo, Lulu Huang, Xia Bai, Miao Jiang, Depei Wu, Suning Chen et al. · 2021 · Frontiers in Oncology
98. Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth
    John Victor Napoleon, Satish Sagar, Sydney P. Kubica, Lidia Boghean, Smit Kour, Hannah M. King, Yogesh Ashok Sonawane, Ayrianne J. Crawford, Nagsen Gautam, Smitha Kizhake et al. · 2022 · Proceedings of the National Academy of Sciences
99. The Tumor Suppressor, p53, Negatively Regulates Non-Canonical NF-κB Signaling through miRNAInduced Silencing of NF-κB-Inducing Kinase.
    Hanbit Jang, Seulki Park, Jaehoon Kim, Jong-Hwan Kim, Seon‐Young Kim, Sayeon Cho, Sung Goo Park, Byoung Chul Park, Sunhong Kim, Jeong‐Hoon Kim · 2020 · Europe PMC (PubMed Central)
100. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
     Stephen E. F. Spurgeon, Brian G. Till, Peter Martin, Andre Henri Goy, Martin H. Dreyling, Ajay K. Gopal, Michael Leo LeBlanc, John Paul Leonard, Jonathan W. Friedberg, Lawrence Baizer et al. · 2016 · JNCI Journal of the National Cancer Institute